Sirtuin as the target of anti-cancer therapy

<p>Sirtuins is a group of nicotinamide dinucleotide (NAD +) - dependent, which have deacetylation and ADP-ribosylation activity. They work by detaching the acetyl group from the lysine residue of the histones, thanks to which they influence the control of gene expression. There are 7 classes o...

Full description

Bibliographic Details
Main Authors: Marzena Baran, Paulina Anna Miziak, Katarzyna Bonio
Format: Article
Language:English
Published: Kazimierz Wielki University 2020-08-01
Series:Journal of Education, Health and Sport
Subjects:
Online Access:https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/31011
Description
Summary:<p>Sirtuins is a group of nicotinamide dinucleotide (NAD +) - dependent, which have deacetylation and ADP-ribosylation activity. They work by detaching the acetyl group from the lysine residue of the histones, thanks to which they influence the control of gene expression. There are 7 classes of sirtuins due to the type of enzymatic activity and the cellular compartment in which they occur. They have a significant impact on the cell cycle, cellular process, including glucose metabolism, fat differentiation, fatty acid oxidation, neurogenesis, carcinogenesis and the aging process. Due to its unique properties, compounds are sought that can control the concentration of sirtuins in the body. One of such substances is resveratrol. It is a naturally occurring polyphenol that has a number of positive effects on the body. It works by increasing the concentration of NAD +, which is a sirtuin cofactor. It occurs naturally, and its greatest concentration is found in grapes and peanuts. It has a beneficial effect in the treatment of pancreatic, colon, breast, prostate and liver cancer. Research indicates that there is a potential for resveratrol supplementation to have positive health effects. However, there is still a need for more research on resveratrol, particularly in animal models. Determining the effectiveness of this chemical as an anti-cancer agent can be a major area of research and clinical trials.</p>
ISSN:2391-8306